Loading company
IceCure Medical Ltd.
ICCM · Nasdaq · ·
$1.60-3.3%Sep 29 close
- 1M
- -30.4%
- 6M
- -81.0%
- 1Y
- -94.7%
- 5Y
- -99.5%
ICCM · Nasdaq · ·
$1.60-3.3%Sep 29 close
From the company’s own 6-K filing.
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company’s flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K IceCure Medical Ltd. filed on November 19, 2025 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
IceCure Medical Ltd. has no earnings call transcript available.